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These electrophysiological experiments, in slices and intact animals, study the effects of in vivo chronic exposure tonicotineon functional
42* nAChRs in the nigrostriatal dopaminergic (DA) pathway. Recordings were made in wild-type and 4 nicotinic acetylcholine
receptor (nAChR) subunit knock-out mice. Chronic nicotine enhanced methyllycaconitine citrate hydrate-resistant, dihydro--
erythroidine hydrobromide-sensitive nicotinic currents elicited by 3–1000 M ACh in GABAergic neurons of the substantia nigra pars
reticulata (SNr), but not inDAneurons of the substantia nigra pars compacta (SNc). This enhancement leads to higher firing rates of SNr
GABAergic neurons and consequently to increased GABAergic inhibition of the SNc DA neurons. In the dorsal striatum, functional4*
nAChRs were not found on the neuronal somata; however, nicotine acts via 42* nAChRs in the DA terminals to modulate glutamate
release onto themedium spiny neurons. Chronic nicotine also increased the number and/or function of these42* nAChRs. These data
suggest that in nigrostriatal DA pathway, chronic nicotine enhancement of42* nAChRs displays selectivity in cell type and in nAChR
subtype aswell as in cellular compartment. These selective events augment inhibition of SNcDAneurons by SNrGABAergic neurons and
also temper the release of glutamate in the dorsal striatum. The effects may reduce the risk of excitotoxicity in SNc DA neurons andmay
also counteract the increased effectiveness of corticostriatal glutamatergic inputs during degeneration of theDA system. These processes
may contribute to the inverse correlation between tobacco use and Parkinson’s disease.
Introduction
Parkinson’s disease (PD) is caused by degeneration of dopami-
nergic (DA) neurons in the substantia nigra pars compacta
(SNc). Neuroprotective therapies are being sought to slow or
delay the progression of PD (Wu and Frucht, 2005; Bonuccelli
and Del Dotto, 2006).
A person’s history of tobacco use is strongly anticorrelated to
his/her risk of Parkinson’s disease (Ritz et al., 2007; Thacker et al.,
2007). Smoked or smoke-cured tobacco is not amedically accept-
able therapy. Therefore, it is important to understand the appar-
ent inadvertent neuroprotective and/or therapeutic mechanism
of chronic exposure to nicotine. In animalmodels of PD, chronic
exposure to nicotine protects DA neurons and terminals (Quik et
al., 2007; Picciotto and Zoli, 2008) and also shows some thera-
peutic benefits, improvingmotor symptoms, ameliorating dyski-
nesia, and boosting L-DOPA efficacy (Quik et al., 2007, 2008).
Hyperactivity of glutamatergic synapses may contribute to PD
symptoms, because some glutamatergic receptor antagonists also
control PD (Parsons et al., 1999; Steece-Collier et al., 2000; Hadj
Tahar et al., 2004; Wu and Frucht, 2005).
The longest-known effect of chronic nicotine is upregulation
of nicotinic receptors themselves. Among the several subtypes of
nAChRs expressed in brain, chronic exposure to smoked doses of
nicotine does not markedly upregulate 7* (Marks et al., 1986;
Collins et al., 1994), 34*, or 6* nAChRs (Nguyen et al., 2003;
McCallum et al., 2006a,b;Mugnaini et al., 2006; Perry et al., 2007;
Walsh et al., 2008) but does effectively upregulate42* nAChRs
in some cell types and brain regions (the asteriskmeans that there
may be other subunits in the pentameric nAChR). For instance,
chronic nicotine upregulates 42* nAChRs in hippocampus,
cortex, striatum, hypothalamus, and midbrain, but not in inter-
peduncular nucleus, medial habenula, or cerebellum (Flores et
al., 1992;Marks et al., 1992; Perry et al., 1999; Nguyen et al., 2004;
Nashmi et al., 2007). Importantly, the neuroprotective effect of
chronic nicotine vanishes in 4 subunit knock-out (KO) mice
(Ryan et al., 2001). In addition to (or possibly because of) 42*
nAChR upregulation, chronic nicotine enhances synaptic plas-
ticity in hippocampus (Fujii et al., 1999; Nashmi et al., 2007),
increases nicotine-induced DA release in striatum (Marshall et
al., 1997; Visanji et al., 2006), and increases firing in midbrain
GABAergic neurons (Nashmi et al., 2007).
How might upregulation of 42* nAChRs protect DA neu-
rons? Upregulation couldmodify activity in neural circuits in the
basal ganglia (Nashmi et al., 2007). To understand how such
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changes could lead to neuroprotection, we chronically infused
mice with nicotine or vehicle and electrophysiologically exam-
ined the function of 42* nAChRs in substantia nigra neurons
and striatal DA terminals. The data reveal that by selectively up-
regulating 42* nAChRs, chronic nicotine exaggerates inhibi-
tion to SNcDAneurons and also tempers the release of glutamate
in the dorsal striatum. These events could reduce the risk of ex-
citotoxicity in SNc DA neurons and would counteract the hyper-
activity of striatal glutamate synapses after DA denervation and
therefore could confer the apparent neuroprotective effects of
chronic nicotine on PD.
Materials andMethods
The care and use of animals and the experimental protocol of this study
were approved by the Institutional Animal Care and Use Committee of
the California Institute of Technology. All efforts weremade tominimize
animal suffering and to reduce the number of animals used.
Patch-clamp recording. The recordings were performed using brain
slices which were prepared from 5–12-week-old C57BL/6 [wild-type
(WT)] mice or 4 nAChR subunit knock-out mice (4-KO mice, back-
crossed N10 to C57BL/6), by using the protocol described previously
(Ye et al., 2006; Nashmi et al., 2007). In brief, the mice were deeply
anesthetized by Nembutal (35 mg/kg) and decapitated. The brain was
removed and sliced in the coronal plane (300 m) with a microslicer
(DTK-1000, Ted Pella Inc.), while immersed in ice-cold modified
glycerol-based artificial CSF (ACSF) saturatedwith 95%O2/5%CO2 (car-
bogen) containing the following (in mM): 250 glycerol, 2.5 KCl, 1.2
NaH2PO4, 1.2 MgCl2, 2.4 CaCl2, 26 NaHCO3, and 11 glucose. Brain
slices (three to four permouse) containing cortex andmidbrain or dorsal
striatum were allowed to recover at 31°C for at least 1 h in a holding
chamber before they were placed in the recording chamber and super-
fused (1.5–2.0 ml/min) with carbogen-saturated ACSF. The recovering
bath was filled with carbogenated ACSF containing the following (in
mM): 125 NaCl, 2.5 KCl, 1.2 NaH2PO4, 1.2 MgCl2, 2.4 CaCl2, 26
NaHCO3, and 11 glucose.
The neurons were visualized with an upright microscope (BX50WI,
Olympus) andnear-infrared illumination.Whole-cell patch-clamp tech-
niques were used to record electrical activity with MultiClamp 700B
amplifiers (Axon Instruments, Molecular Devices), Digidata 1200 analog-
to-digital converters (Axon Instruments), and pCLAMP 9.2 software
(Axon Instruments). Data were sampled at 10 kHz and filtered at 2 kHz.
The junction potential between the patch pipette and the bath solutions
was nulled just before we formed the gigaseal.
The patch electrodes had resistances of 5–8 M when filled with in-
trapipette solution 1, which contained the following (in mM): 135 potas-
siumgluconate, 5 KCl, 5 EGTA, 0.5CaCl2, 10HEPES, 2Mg-ATP, and 0.1
GTP; or with solution 2, which contained the following (inmM, for IPSC
recordings): 75 K gluconate, 65 KCl, 5 EGTA, 0.5 CaCl2, 10 HEPES, 2
Mg-ATP, 0.1 GTP, and 2 mM QX-314. The pH of these solutions was
adjusted to 7.2 with Tris base and the osmolarity to 300 mOsm with
sucrose. Nernst potentials for Cl in solutions 1 and 2 are 82.9 and
18mV, respectively. Therefore, spontaneous inward currents recorded
at the holding potential of60 to70 mV include, for solution 1, only
EPSCs, and for solution 2, both IPSCs and EPSCs.
Series resistance was monitored and compensated by 70–80%
throughout whole-cell patch-clamp recordings (Multiclamp 700B). The
data were discarded if the series resistance (15–30 M) changed by
20% during the whole-cell recording. Given the modest size of the
sIPSCs, mIPSCs, sEPSCs, and eEPSPs in this study, these conditions
produced minimal distortion of the waveforms (Takahashi et al., 1995).
The bath was continuously perfused with ACSF. All recordings were
done at a temperature of 32 1°C.
In the midbrain slice, we identified the type of neurons in SNc and
substantia nigra pars reticulata (SNr) according to the following criteria
(Lacey et al., 1989; Nashmi et al., 2007): (1) spontaneous firing rate is
higher in GABAergic neurons (5Hz) than in DA neurons (5Hz); (2)
the action potential is briefer (2ms) in GABAergic neurons than inDA
neurons (2 ms); (3) a prominent hyperpolarization-induced cationic
current (Ih) appears in DA neurons but not in GABAergic neurons; (4)
GABAergic but not DA neurons are inhibited by Tyr-D-Ala-Gly-MePhe-
Gly-ol (DAMGO), a-opioid receptor agonist; (5) DA but not GABAer-
gic neurons are inhibited by quinpirole, a dopamine D2/D3 receptor
agonist.
In the dorsal striatum slice recordings, we identified striatal neurons
according to their distinct electrophysiological properties (Jiang and
North, 1991; Nisenbaum andWilson, 1995; Koo´s and Tepper, 1999). (1)
Medium spiny neurons (MSNs) have comparatively hyperpolarized
membrane potentials (75 to 85 mV), a comparatively low input re-
sistance (100 M), inward rectification (smaller response to negative
than to positive current pulses), and, for rheobase stimuli, a gradually
developing depolarization and comparatively long latency to the first
spike (see Fig. 4A1). (2) Fast-spiking (FS) interneurons have compar-
atively hyperpolarized membrane potentials (75 to85 mV), tran-
sient postspike hyperpolarizations, and comparatively brief interspike
intervals (see Fig. 4B1). (3) Cholinergic interneurons have membrane
potentials of55 to65 mV and voltage sag due to Ih in response to
hyperpolarizing current injection (see Fig. 4C1). (4) Low-threshold-
spike (LTS) interneurons have membrane potentials of 60 to 70
mV, a comparatively high input resistance (200M), and no Ih (see
Fig. 4D1).
We optimized several conditions for subsecond assessments of nAChR
sensitivity. We measured responses to ACh rather than to nicotine,
avoiding distortions due to passive nicotine accumulation and release by
neurons. We also added atropine to block muscarinic acetylcholine re-
ceptors. Responses were tested using a focal, relatively rapid drug appli-
cation system designed tominimize desensitization (Tapper et al., 2004).
Briefly, a 2-m-tip glass pipette filled with ACSF containing ACh (3
M–1 mM), atropine (0.5 M), and 20 M 6,7-dinitroquinoxaline-2,3-
dione (CNQX) was mounted on a piezoelectric manipulator and con-
nected to a controlled source of pressure. The pipette was moved from a
starting position (100 m from the recorded neuron) to a “puffing
position” (20 m from the recorded neuron), acetylcholine was ap-
plied by a pressure pulse (20 psi, 100ms), and then, the pipette was again
retracted to the starting position. We used 100 ms puffs because longer
puffs did not increase the peak current. We applied ACh at 3 min inter-
vals to minimize desensitization. Although repetitive applications of 1
mM ACh did not cause desensitization of nicotinic responses, repeated
application of 3 and 10 mM ACh did produce 15% decrement in suc-
cessive responses. Therefore, the dose–response studies used concentra-
tions of1 mM ACh.
Chronic nicotine treatment. Nicotine or vehicle (saline) was adminis-
tered to mice (4–11 weeks old) by subcutaneously implanted mini-
osmotic pumps (model 2002,Alzet, Cupertino,CA) for 10–14d (Nashmi et
al., 2007). Formidbrain slice recordings, we studied 4–6-week-oldmice.
For other recordings, we studied 8–12-week-old mice. On the day of
minipump implantation, vehicle or () nicotine hydrogen tartrate salt
was prepared freshly and loaded into the pump to deliver vehicle or
nicotine (2 mg/kg/h at 0.5l/h). This produces a blood concentration of
590 nM (Marks et al., 2004), near the peak concentration of nicotine in
the blood of smokers. This method provides consistent nicotine dosage
and effectively induces cellular, molecular, and systemic changes related
to tobacco use (Fung and Lau, 1988; Collins et al., 1994; Nguyen et al.,
2003, 2004; Marks et al., 2004; Nashmi et al., 2007) but limits the influ-
ence of stress from repeated nicotine injection.
In each set of experiments, we implanted minipumps in mice (three
for each treatment) almost at the same age (2 d). The electrophysiolo-
gist recorded from onemouse per day and alternated betweenmice from
the vehicle- and nicotine-treated groups (but without knowing the treat-
ment), thus maintaining the same average mouse age and treatment
period for data from the two groups. Surgical treatments and electro-
physiological experiments were performed by separate individuals who
did not share records (S.M. and C.X., respectively) until the data had
been summarized, thus achieving “blind” experiments.
Single-unit extracellular recording in vivo. After 10–14 d of chronic
administration of vehicle or nicotine, mice were anesthetized with chlo-
ral hydrate (400 mg/kg, i.p.), and the minipumps were removed. When
the mice awakened, ketoprofen (2 mg/kg), an analgesic, was subcutane-
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ously injected for pain relief. One day later, the mice were anesthetized
again and immobilized in a stereotaxic frame (Stoelting). Body temper-
ature was monitored and maintained at 37.0  0.1°C by a heated plate
(WPI). A hole (1 mm in diameter) for the placement of recording elec-
trode was drilled, centered at 3.2 mm posterior to bregma and 1.0 mm
lateral to the midline on the skull. The dura was opened over the record-
ing sites. To maintain deep anesthesia, chloral hydrate was intraperito-
neally injected at 100 mg/kg/30 min.
Extracellular potentials were recorded by a single recording micropi-
pette filled with 3 M NaCl mounted on a Narishige hydraulic microdrive.
Signals were led to an Axoclamp-2A amplifier, then to a Brownlee Preci-
sion Model 440 amplifier, and then to a Digidata 1200 digitizer con-
trolled by pCLAMP 9.2 (Axon Instruments) software. The recording
electrode was positioned via stereotaxic coordinates into the substantia
nigra (from bregma: 3.0–3.4 mm posterior, 0.5–1.5 mm lateral, and
4.0–5.0 mm ventral) (Paxinos and Franklin, 2004). The signals were
sampled at 20 kHz and bandpass filtered at 1Hz–10 kHz. In analyses of in
vivo single-unit recordings, the spikes of SNr GABAergic neurons were
identified by high frequencies (5 Hz), brief duration (2 ms), and
insensitivity to quinpirole (supplemental Fig. S1, available at www.
jneurosci.org as supplemental material).
Immunohistochemistry. The 4-YFP mice (Nashmi et al., 2007) were
anesthetized with halothane (2-bromo-2-chloro-1,1,1-trifluorothane)
and subjected to cardiac perfusion with 7 ml of PBS with heparin and
then with 30 ml of 4% paraformaldehyde in PBS. The mouse brain was
removed, fixed in 4% paraformaldehyde for 2 h, and immersed in 30%
sucrose in PBS for 24–48 h till sink. After being rapidly frozen in
2-methylbutane (40°C), the mouse brain was sectioned into 30 m
coronal slices by using a sliding microtome (Leica SM 2010R).
The slices were washed twice (10 min each) with cold PBS (4°C),
permeabilized for 1 h at room temperature in PBS/0.5% saponin,
blocked for 1 h in 10% donkey serum in PBS, incubated in primary
antibodies at 4°C overnight (18 h): sheep anti-tyrosine hydroxylase (TH)
(1:500, Alzheimer Research Forum) and rabbit anti-GFP (1:300, Abcam)
in 4% donkey serum in PBS, washed three times (15 min each) in PBS,
incubated in secondary antibody at room temperature for 1.5 h: Cy3-
conjugated donkey anti-sheep IgG (1:500), and Cy5-conjugated donkey
anti-rabbit IgG (1:500) in PBS/4%donkey serum,washed three times (10
min each) in PBS, and then mounted onto the slide and coverslipped with
mountingmedium (Vector Laboratories).We imaged the sliceswith a spec-
trally resolved confocalmicroscope (NikonC1si), equippedwith a 60, 1.4
numerical aperture, planapochromatoil-immersion objective. Cy3 orCy5
was excited with a 514 or 637 nm laser and detected in the range of
520–680 nm or 640–720 nm. The acquired images were linearly un-
mixed with reference spectra using EZ-C1 software (Nikon). We ob-
tained the reference spectra of Cy3 from midbrain dopaminergic
neurons in brain slices processed for TH staining with or without added
TH antibody, and those of Cy5 from midbrain neurons in slices of 4-
YFP mice or their wild-type littermates, processed for GFP staining. The
specificity of the anti-GFP staining is shown in supplemental Fig. S2,
available at www.jneurosci.org as supplemental material, which con-
trasts the images for 4-YFP and WT mice.
Chemicals and applications. Sigma-Aldrich furnished most of the
chemicals including acetylcholine chloride (ACh), CNQX, dihydro--
erythroidine hydrobromide (DHE), mecamylamine hydrochloride
(MEC), methyllycaconitine citrate hydrate (MLA), ()-nicotine hydro-
gen tartrate salt, picrotoxin, SR-95531 (GABAzine), ()-sulpiride, and
tetrodotoxin (TTX). The chemicals were added in known concentrations
to the superfusate.
Data analysis.Using Clampfit 9.2, we measured the peak amplitude of
nicotinic currents and counted and analyzed spontaneous/miniature
inhibitory/EPSCs (sIPSCs/mIPSCs, sEPSCs) and firing. The sIPSCs,
mIPSCs, sEPSCs, and action potentials were selected by “template
search,” in which the template was first selected visually according to its
rise and decay phase, and amplitude threshold was set to 5 pA for sIPSCs/
mIPSCs/sEPSCs, and 10 mV for action potentials. The frequencies of
sIPSCs, sEPSCs, mIPSCs, and firings during and after drug applications
were normalized to their mean values observed during the initial control
period (2 min). These data were used to depict summarized time
courses (10 s/bin). The baseline mean values were obtained during the
initial control period, while the mean values during drug application
were obtained over a2min period at the peak of a drug response. Drug
effects were expressed as percentage change (mean  SEM) from base-
line. The statistical significance of drug effects was assessed by a paired
two-tailed t test. A two-tailed t test was also used to evaluate the statistical
significance of differences in drug effects (percentage change from base-
line) in two different situations, e.g., the absence and presence of block-
ers, or chronic nicotine and vehicle treatments. p values of 0.05 were
considered significant.
The sIPSCs and sEPSCs displayed awide range of amplitudes. To show
all the events in the figures, we used an amplification that clipped a few
large responses. For amplitude determinations, unclipped data were
measured.
The in vivo single-unit recording data were analyzed using Clampfit
9.2 after high-pass (10Hz) and low-pass (3 kHz) filtering. A template was
made by averaging 20 spikes with apparently similar waveforms and
amplitudes and used for automatic spike detection. Sometimes, the re-
corded trace displayed several classes of spikes with different waveforms,
amplitudes, or both.We defined several spike templates (3) and simul-
taneously analyzed them. For each neuron, the firing rate was calculated
from 3–5 min stable recording. The spike duration was determined by
measuring the time between half-peak amplitude for the falling and ris-
ing edges. The significance of the difference in firing frequencies of SNr
GABAergic neurons between chronic nicotine- and vehicle-treated mice
was analyzed with a t test.
Results
Chronic nicotine selectively enhances 42* nAChRs in
SNr GABAergic neurons
Midbrain GABAergic neurons express multiple subtypes of
nAChRs, including 7 and 42* (Pidoplichko et al., 1997;
Azam et al., 2002; Wooltorton et al., 2003; Dani and Bertrand,
2007; Nashmi et al., 2007) but not 62* (Drenan et al., 2008).
Therefore, to record nicotinic currents mediated by 42*
nAChRs, we puffed ACh to SNr GABAergic neurons in the pres-
ence of MLA (10 nM), a specific antagonist for 7 nAChRs, and
atropine (0.5M), an antagonist of muscarinic ACh receptors. In
this recording condition, the nicotinic current evoked by 1 mM
ACh was eliminated by DHE (300 nM), an antagonist for 2*
nAChRs (Fig. 1A1). We also conducted experiments with 4-KO
mice. In the absence of nicotinic blockers, we detected fast ACh-
induced currents in 12 of 14 SNr GABAergic neurons. These
currents were completely blocked by MLA (10 nM) (Fig. 1A2).
These data suggest that MLA-resistant nicotinic currents in WT
SNr GABAergic neurons are primarily mediated by 42*
nAChRs.
Chronic nicotine increases the number of fluorescent 4*
nAChRs in SNr GABAergic neurons (Nashmi et al., 2007). To
directly assess the function of these nAChRs, wemeasuredMLA-
resistant nicotinic currents in SNr GABAergic neurons (Fig.
1A1,B1,B2). As illustrated in Figure 1, B1, B2, and C1, and Table 1,
ACh induced larger currents in chronic nicotine-treated mice
than chronic vehicle-treated mice, and this increase occurred at
all concentrations from 3 M to 1 mM. Because desensitization
limited the precision of the measurements for [ACh] 1 mM,
while the ACh bolus was spreading to distant parts of the neuron,
we did not obtain a true “saturating” dose–response relation.
Dose–response relations for 42 nAChRs expressed in vitro are
typically comprised of two or more components. One mM ACh
exceeds the EC50 of the higher- and lower-sensitivity components
by 1000-fold and 10-fold, respectively (Buisson and Bertrand,
2001; Rodrigues-Pinguet et al., 2003;Moroni et al., 2006), so that
the 1 mM responses presumably reflect nearly full activation of
nAChRs that were reached by the ACh bolus. At 1 mM ACh, the
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responses from chronic nicotine-treated animals were 41%
higher than from chronic vehicle-treated animals. This value
agrees well with the 46% increase of 4* nAChR fluorescence
measured under equivalent conditions by Nashmi et al.
(2007), consistent with the idea that the increased ACh re-
sponses measured in this study corre-
spond to the numerically upregulated
4* nAChRs measured by Nashmi et al.
(2007). We compared the waveform
of MLA-resistant nicotinic currents in-
duced by 1 mM ACh in SNr GABAergic
neurons. The decay time constant showed
little or no difference between chronic
vehicle- and nicotine-treated mice (1011 
115 ms, n 14; and 853 45 ms, n 20,
respectively).
To compare the effects of chronic
nicotine on lower- and higher-sensitivity
42*nAChRs,wealsonormalized thenic-
otinic currents to those induced by 1 mM
ACh in the same neuron. Interestingly,
the normalized responses at 3 and 10
M, but not higher concentrations, were
significantly increased by chronic nico-
tine (Fig. 1C2, Table 1). Apparently
higher-sensitivity 42* nAChR(s) is
preferentially upregulated by chronic
nicotine. Our data lack the precision
to state whether the increased high-
sensitivity component alone can explain
the enhancement by chronic nicotine at
all ACh concentrations.
Chronic nicotine appears to selectively
upregulate fluorescent 4* nAChRs in
SNr GABAergic neurons but not in SNc
DA neurons (Nashmi et al., 2007). To test
the cell type selectivity of chronic nicotine
effects on 4* nAChR function, we also
examined MLA-resistant nicotinic cur-
rents from SNc DA neurons (Fig.
1D1,E1,E2). In contrast to its effect in SNr
GABAergic neurons, chronic nicotine did
not change the currents induced by puff-
ing 30, 100, and 1000 M ACh onto SNc DA neurons (Fig. 1F,
Table 2).
We next tested whether 4* nAChRs principally mediate
MLA-resistant nicotinic currents in SNcDAneurons.We elicited
nicotinic currents with 1 mM ACh in SNc DA neurons of 4-KO
mice. Three pharmacological classes were observed in the nico-
tinic currents tested in nine neurons: complete blockade by 10 nM
MLA alone (in two neurons) (data not shown), by 0.3MDHE
alone (in five neurons) (Fig. 1D2), and by the combination of
MLA and DHE (two neurons) (data not shown). The currents
sensitive to 0.3 M DHE (33.7  2.2 pA, n  7) were also
sensitive to 0.1 M -conotoxin MII, a selective blocker of 6*
nAChRs (Fig. 1D2). This indicates that MLA-resistant nicotinic
currents in WT SNc DA neurons are mediated primarily by
42* nAChRs, with a detectable contribution from (non-4)
62* nAChRs. The data are consistent with previous findings
that midbrain DA neurons express functional 6* nAChRs
(Klink et al., 2001; Champtiaux et al., 2003; Drenan et al., 2008).
Interestingly, the experiments on4-KOmice showed that (non-
4) 62* nAChRs were significantly downregulated by chronic
nicotine (1 mMACh-induced nicotinic currents, chronic vehicle:
33.7 2.2 pA, n 7; chronic nicotine: 17.0 0.6 pA, n 4; p
0.001) (data not shown). This apparent nicotine-induced down-
regulation of6* receptors is consistent with some (McCallum et
al., 2006a,b; Mugnaini et al., 2006) but not other (Visanji et al.,
Figure 1. Chronic nicotine modifies nicotinic currents in substantia nigra neurons. Nicotinic currents in response to puff appli-
cation of 1mM AChwere recorded from voltage-clamped substantia nigra neurons (VH60mV) inmidbrain slices ofWTmice
(A1, B1, B2, D1, E1, and E2 in the presence of 10 nMMLA) and4-KOmice (A2 and D2). A1, DHE (0.3M) blockedMLA-resistant
nicotinic currents in SNr GABAergic neurons of WT mice. A2, Nicotinic currents in SNr GABAergic neurons of 4-KO mice were
blocked byMLA (10 nM).B1,B2, Typical nicotinic responses, elicited by 10Mand1mMACh, recorded fromSNr GABAergic neurons
in chronic vehicle-treated (B1) and nicotine-treated (B2) mice. C1, Dose–response relations of MLA-resistant nicotinic currents in
SNr GABAergic neurons of chronic nicotine (solid circle)- and vehicle (open circle)-treated WT mice. C2, MLA-resistant currents
elicited by lower ACh concentrations as a percentage of 1 mM ACh responses. D1, DHE (0.3M) blocked MLA-resistant nicotinic
currents in SNc DA neurons ofWTmice.D2, In seven of nine SNc DA neurons of4-KOmice, MLA-resistant nicotinic currents were
blocked by either DHE (0.3M) or-conotoxin MII (Ctx MII, 0.1M). The data in the two panels were recorded from the same
neuron. E1, E2, Typical nicotinic responses, elicited by 30M and 1 mM ACh, recorded from SNc DA neurons in chronic vehicle-
treated (E1) and nicotine-treated (E2) mice. F, Dose–response relations of MLA-resistant nicotinic currents in SNc DA neurons of
chronic nicotine (solid circle)- and vehicle (open circle)-treatedWTmice. Arrows indicate the application of ACh. Data in summary
are shown as mean SEM. *p 0.05, **p 0.01, chronic nicotine- versus vehicle-treated mice.
Table 1. Nicotinic currents in SNr GABAergic neurons
ACh
(M)
Chronic vehicle Chronic nicotine
IACh (pA) % IACh (1 mM) n IACh (pA) % IACh (1 mM) n
3 7.8 1.6 3.6 0.5 3 23.7 5.4* 7.4 0.5** 5
10 20.5 3.8 9.7 1.2 6 43.9 1.9** 16.6 0.5** 5
30 45.0 4.9 19.9 2.0 8 91.9 15.0* 24.0 3.0 9
100 107.0 12.0 39.9 8.0 8 172.0 36.0* 43.4 4.0 9
300 135.0 31.0 68.0 14.0 4 185.5 24.3 75.4 11.5 3
1000 213.5 20.5 1 19 300.8 28.8* 1 19
*p 0.05, **p 0.01, compared with chronic vehicle-treated mice.
Table 2. Nicotinic currents in SNc DA neurons
ACh (M)
Chronic vehicle Chronic nicotine
IACh (pA) n IACh (pA) n
30 32.8 5.5 5 30.5 4.5 6
100 61.9 9.8 9 60.0 8.4 5
1000 121.0 17.6 10 139.0 9.0 8
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2006; Perez et al., 2008) previous studies.
Because the (non-4) 62* nAChR re-
sponse is a small fraction of the total
non-7 nicotinic response in WT DA
neurons, any up- or downregulation of
(non-4) 62* nAChRs would escape
detection in the response of DA neurons
to chronic nicotine.
In a test of the hypothesis that only4*
receptors are upregulated by chronic nic-
otine, we measured MLA-sensitive nico-
tinic currents in SNr GABAergic neurons
of 4-KO mice (Fig. 1A2). Chronic nico-
tine did not change 1 mM ACh-evoked
currents (chronic vehicle: 34.0  14.0,
n  4; chronic nicotine: 39.0  8.1 pA,
n 8; p 0.38). The data agree with pre-
vious findings that chronic exposure to
nicotine with the protocol we were using
selectively upregulates 42* but not 7
nAChRs (Marks et al., 1986; Collins et al.,
1994).
Chronic nicotine acting via SNr
GABAergic neurons inhibits SNc
DA neurons
Some 42 nAChRs are activated by
comparatively low concentrations of ACh
or nicotine (Buisson and Bertrand, 2001;
Nelson et al., 2003; Moroni et al., 2006).
As shown in Figure 1, C1 and C2, and Ta-
ble 1, chronic nicotine enhanced MLA-
resistant nicotinic currents and the ratio
of low ACh (10 M) to 1 mM ACh-
induced currents in SNr GABAergic neu-
rons. This enhancement of sensitivity may be important in
cholinergic modulation of neuronal activity by the relatively low
concentrations (100 nM measured by in vivo microdialysis) of
ambient ACh (Descarries et al., 1997; Dani and Bertrand, 2007).
To address this issue, we recorded the firing of these neurons
using both in vitro brain slice patch-clamp recordings and in vivo
single-unit recordings. In chronic nicotine-treated mice, both in
vitro and in vivo SNr GABAergic neurons fire at higher frequen-
cies than in chronic vehicle-treatedmice (Fig. 2A1,A2,C). In con-
trast, SNc DA neurons in midbrain slices fire more slowly in
chronic nicotine-treated mice (1.97  0.31 Hz, n  29) than in
vehicle-treated mice (2.84 0.42 Hz, n 38) ( p 0.003) (Fig.
2D1,E). These results on firing rates agree with a previous report
(Nashmi et al., 2007).
Nicotine modulates sIPSCs in DA neurons by activating
42* nAChRs in GABAergic neurons (Mansvelder et al., 2002).
The hypothesis that the major effect of chronic nicotine on
GABAergic neurons is mediated by the upregulation of 4*
nAChRs predicts that the effects of chronic nicotinewill be absent
from 4-KO mice. We therefore measured the firing of SNr
GABAergic and SNc DA neurons in in vitro midbrain slices of
4-KO mice. We detected little difference between the basal fir-
ing rates of SNr GABAergic neurons from chronic vehicle-treated
4-KO versus WT mice (Fig. 2A1,A2,B,C). SNc DA neurons
from chronic vehicle-treated4-KOmice fired at approximately
half the frequency of their counterparts from WT mice (Fig.
2D1,D2,E), consistent with the high-level expression of 4*
nAChRs in DA neurons (Nashmi et al., 2007). In 4-KO mice,
chronic exposure to nicotine changed neither the firing fre-
quency of SNr GABAergic neurons (chronic nicotine: 13  1.4
Hz, n 24; chronic vehicle: 15.7 1.8Hz, n 22, p 0.26) (Fig.
2B,C) nor that of SNcDAneurons (chronic nicotine: 1.53 0.14
Hz, n  29; chronic vehicle: 1.58  0.16 Hz, n  26; p  0.41)
(Fig. 2D2,E). These data suggest that, in WT mice, the effect of
chronic nicotine on the activity of both SNr GABAergic neurons
and SNc DA neurons is mediated by its effect on 4* nAChRs.
That is, chronic nicotine selectively upregulates 42* nAChRs
and enhances the firing rate in SNr GABAergic neurons, which
may cause stronger inhibition to SNcDA neurons (Nashmi et al.,
2007). The blockade of GABAA receptors by 10 M GABAzine
excited SNc DA neurons (Fig. 2F). In the presence of GABAzine,
the firing rates of SNc DA neurons were equal in chronic
nicotine- and vehicle-treated mice (Fig. 2F). These data indicate
that chronic nicotine enhancement of firing frequency in
GABAergic neuronsmay contribute to the depression of firing in
SNc DA neurons.
Further experiments support the idea that a presynaptic
mechanismunderlies chronic nicotine enhancement ofGABAer-
gic inhibition to SNc DA neurons. The sIPSCs were recorded
from voltage-clamped SNcDA neurons (VH60mV) inmid-
brain slices, in the presence of 20 M CNQX. In the same me-
dium, the eIPSCs were stimulated by pulses from a glass pipette
electrode filled with 2 MNaCl and placed in the SNr 100maway
from the recorded neuron. The mIPSCs were recorded in the
presence of 0.5 M TTX to block action potential-dependent
sIPSCs. The sIPSCs, eIPSCs, and mIPSCs were blocked by 10 M
Figure 2. Chronic nicotinemodifies firing rates in substantia nigra neurons: the role of4* nAChRs. The spikes were recorded,
usingwhole-cell patch-clamp technique, from substantia nigra neurons inmidbrain slices ofWT (A1,D1, and F ) and4-KO (B and
D2) mice, and also with SNr GABAergic neurons in vivo by using single-unit extracellular recording (A2). A1, A2,B, Chronic nicotine
increases the firing rate of SNr GABAergic neurons inmidbrain slices (A1) and in vivo (A2), but not inmidbrain slices of4-KOmice
(B). C, Summary of data. D1, D2, E, In contrast, chronic nicotine decreases the activity of SNc DA neurons in WT mice (D1, pooled
data; E, summary), but not in4-KOmice (D2, pooled data; E, summary). F, Summarized time course showing that GABAzine (10
M, a GABAA receptor blocker) eliminated the difference in the baseline firing rate of SNc DA neurons between chronic nicotine-
and vehicle-treated WT mice. Data in summary are shown as mean SEM. ns, Not significant, chronic nicotine- versus vehicle-
treated mice.
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bicuculline (data not shown). First, chronic nicotine increased
the baseline frequency of sIPSCs (chronic nicotine: 3.25  0.43
Hz, n  35; chronic vehicle: 1.9  0.31 Hz, n  25) ( p  0.01)
(Fig. 3A1,A3) but not the amplitude of sIPSCs (chronic nicotine:
14.9  1.6 Hz, n  35; chronic vehicle: 14.9  1.3 Hz, n  25)
( p  0.5) (data not shown). Second, chronic nicotine did not
change the frequency of mIPSCs (chronic nicotine: 1.06 0.15 Hz,
n 9; chronic vehicle: 0.84 0.17, n 7) (Fig. 3A2,A3). Third,
the maximal evoked IPSCs were not significantly different be-
tween chronic nicotine-treated (480 70 pA, n 9) and vehicle-
treated (471 71 pA, n 9) mice ( p 0.48) (Fig. 3B). Fourth,
we found that DHE (0.3 M) significantly inhibited sIPSC fre-
quency in SNc DA neurons (by 22 3%, n 6, p 0.003) (Fig.
3C). Interestingly, chronic nicotine enhanced this inhibition (to
36  4%, n  7, p  0.0001) ( p  0.02, chronic nicotine vs
vehicle) (Fig. 3C).
The data reported in this section are all consistent with the
ideas (1) that chronic nicotine suppresses the firing of WT SNc
DA neurons by upregulating the number and/or sensitivity of
42* nAChRs inWTGABAergic neurons, (2) that this upregu-
lation enhances SNr GABAergic inhibitory input (see Fig. 8A,B),
and (3) that chronic nicotine produces no direct change in soma-
todendritic nicotinic responses in SNc DA neurons.
Functional42* nAChRs in the dorsal striatum
Low but detectable levels of 42* nAChR fluorescence are re-
ported in the dorsal striatum (Nashmi et al., 2007). Numerous
studies focus on the 42* nAChRs in DA terminals in the stri-
atum. However, the localization of functional 42* nAChRs in
the striatal neurons has not been systematically studied.
To address this issue, we examined the nicotinic currents in
electrophysiologically identified striatal neurons (Fig. 4A1,B1,
C1,D1) (see Materials and Methods). We detected nicotinic cur-
rents in 32% (12/37) of MSNs (27.6  5.2 pA), 44% (7/16) of
cholinergic interneurons (54.3  10.7
pA), 100% (7/7) of FS interneurons
(58.5  8.2 pA), and 33% (2/6) of LTS
interneurons (219 pA and 19 pA). All of
the currents in MSNs, cholinergic neu-
rons, and FS interneurons were blocked
by MLA (Fig. 4A2,B2,C2,D2) and were de-
sensitized by 10 min perfusion of 1 M
nicotine (38 6% of control, n 4, p
0.001) (Fig. 4E) but not by 0.1 M nico-
tine (97 9% of control, n 3, p 0.45)
(data not shown). In recordings from LTS
interneurons, one response (219 pA) was
blocked by MEC (Fig. 4D2), while the
other one was blocked by MLA (data not
shown). These properties (sensitivity to
MLAand lack of desensitization by 0.1M
nicotine) suggest that the somatoden-
dritic nAChRs in the striatal neurons are
primarily composed of 7 subunits.
We next evoked EPSPs in MSNs with
local electric stimuli. The stimuli were ad-
justed to evoke near-threshold EPSPs,
so that 20–60% of the stimuli produ-
ced postsynaptic spikes (Fig. 5A1,B1,C1).
CNQX (20 M) blocked both EPSPs and
spikes (Fig. 5A1,A2, inset), indicating that
glutamate receptors mediated the EPSPs,
which triggered spikes. Interestingly, both
1 M nicotine and 0.3 M DHE increased the EPSP–spike cou-
pling ratio (nicotine: from 0.36 0.05 to 0.63 0.08, n 8, p
0.001) (Fig. 5A1–A3) (DHE: from 0.46  0.10 to 0.75  0.15,
n 4, p 0.01) (Fig. 5B1–B3). In contrast, 1Mnicotine failed to
enhance the EPSP–spike coupling ratio in 4-KO mice (from
0.49 0.05 to 0.54 0.10, n 5, p 0.21) (Fig. 5C1–C3). These
data indicate that functional nAChRs do exist in the dorsal stria-
tum, contain 4 and 2 subunits, and modulate the excitability
of MSNs. Because (1) we detected no functional 42* nAChRs
in MSN somata and (2) desensitization of functioning nAChRs
would cause repolarization, decreasing the excitability, we hy-
pothesize that the contributing nAChRs are directly or indirectly
presynaptic to the MSNs.
42* nAChRsmodulate glutamate release onto MSNs
The excitability of MSNs is strongly controlled by glutamatergic
excitatory synaptic transmission (Jiang and North, 1991). We
next tested whether nicotine enhanced this glutamatergic trans-
mission. We recorded evoked EPSCs from voltage-clamped
(VH70mV)MSNs.Nicotine (1M)enhancedEPSCamplitudes
by 34 2% (n 3, p 0.002, paired t test) (data not shown). To
discriminate presynaptic versus postsynapticmechanisms of nic-
otine action, we recorded spontaneous EPSCs (sEPSCs). Both 30
nM and 1 M nicotine perfusion (10 min) increased sEPSC fre-
quency, and by a similar extent (1 M: by 44 6%, n 13, p
0.0001) (Fig. 6A1,A3) (30 nM: 35 6%, n 9, p 0.004) (data
not shown), without changing the amplitude of sEPSCs (data not
shown). The presence of MEC at 5 M (a broad spectrum nico-
tinic antagonist) throughout the experiment blocked (or oc-
cluded) nicotine-induced enhancement of sEPSC frequencies
(change of6 4%, n 4, p 0.2) (data not shown). Surpris-
ingly, either of two nAChR antagonists, DHE (0.3 M) or MEC
(5 M), but not MLA (10 nM), significantly enhanced sEPSC
frequency (DHE: by 40 3%, n 8, p 0.003) (Fig. 6B1,B3)
Figure 3. Chronic nicotine augments GABAergic inhibition to SNc DA neurons via presynapticmechanisms. The sIPSCs (A1,A3),
eIPSCs (B), andmIPSCs (A2,A3)were recorded fromSNcDAneurons.A1–A3, Representative traces of sIPSCs (A1),mIPSCs (A2), and
summary of IPSC frequency (A3) in chronic vehicle- andnicotine-treatedmice.B, Averaged traces ofmaximal eIPSCs in all recorded
neurons in chronic vehicle- ornicotine-treatedmice.C, Representative tracesof sIPSCs, showing that chronicnicotineenhanced the
inhibitionof sIPSC frequencybyDHE (0.3M). Summarizeddataare shownasmeanSEM.ns,Not significant, chronic nicotine-
versus vehicle-treated mice.
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(MEC: by 35  11%, n  5, p  0.018) (Fig. 6C1,C2) (MLA: by
4 4%, n 9, p 0.17) (data not shown). Moreover, MEC (5
M) did not alter sEPSC frequency in4-KOmice (change of 4
11%, n  6, p  0.21) (Fig. 6C1,C2). These data suggest that
nicotine facilitated glutamate release via desensitizing 42*
nAChRs that are directly or indirectly presynaptic to MSNs.
The activation of 42* nAChRs on dopaminergic terminals
facilitates DA release in the dorsal striatum (Zhou et al., 2001;
Salminen et al., 2004; Grady et al., 2007; Nashmi et al., 2007;
Drenan et al., 2008); in contrast, desensitization of these recep-
tors reduces DA release (Zhou et al., 2001; Rice and Cragg, 2004;
Zhang and Sulzer, 2004; Exley et al., 2008). We previously
observed low but detectable expression of 4-YFP* nAChRs in
the dorsal striatum (Nashmi et al., 2007); immunostaining for
GFP now confirms that these signals mostly occurred in TH-
immunostained structures (Fig. 6D). These data support the lo-
calization of42* nAChRs in dopaminergic fibers/terminals. In
addition, DA acting via D2/D3 receptors inhibits glutamatergic
terminals (Bamford et al., 2004). We hypothesized that nicotine
(1 M) may modulate glutamate release through this pathway.
That is, nicotine desensitizes 42* nAChRs in DA terminals,
reduces DA release, and therefore indirectly disinhibits gluta-
matergic terminals. We observed that 10M sulpiride, a D2/D3
receptor antagonist, robustly enhanced sEPSC frequency (by
34 3%, n 9, p 0.0001) (data not shown) without changing
the amplitude of sEPSCs (data not shown). This suggests that the
baseline DA level in the dorsal striatum is high enough to inhibit
glutamate release by activating presynaptic D2/D3 receptors
(Bamford et al., 2004; David et al., 2005). Meanwhile, in the
presence of 10M sulpiride, neither nicotine (1M) (Fig. 6A2,A3)
nor DHE (0.3 M) (Fig. 6B2,B3) enhanced sEPSC frequency.
These data suggest that 42* nAChRs on striatal DA terminals
are the primary contributors to nicotine (1 M)modulation of
glutamate release (see Fig. 8C) and that their function can be
indirectly evaluated by this nicotine (1 M) or DHE (0.3 M)
enhancement of glutamate release.
Chronic nicotine upregulates 42* nAChRs on
dopaminergic terminals in striatum
We used the effect described here, indirect modulation of gluta-
mate release by 42* nAChRs, to assess the effects of chronic
nicotine exposure on 42* nAChRs. Interestingly, we observed
that chronic nicotine significantly enhanced the facilitation of
sEPSC frequency by either 1 M nicotine (chronic nicotine: by
50 7%, n 6, p 0.0003; chronic vehicle: by 32 3%, n 8,
p  0.00001) ( p  0.01) (Fig. 7A1,A2) or DHE (0.3 M)
(chronic nicotine: by 52 7%, n 7, p 0.0007; chronic vehi-
cle: by 35  4%, n  8, p  0.0002) ( p  0.03) (Fig. 7B1,B2).
These data agree with previous observations that chronic nico-
tine exposure upregulates 42* nAChRs in the striatum (Fig.
8C,D) (Marshall et al., 1997; Visanji et al., 2006; Nashmi et
al., 2007).
We also noted that the baseline frequency of sEPSCs inMSNs
was significantly reduced in chronic nicotine-treated mice
(2.32  0.16, n  25) when compared with chronic vehicle-
treated mice (2.91 0.22, n 18) ( p 0.02) (Fig. 7C1,C2). This
suggests that endogenous ACh, acting via the upregulated 42*
nAChRs on DA terminals, leads to a higher baseline release of
DA, exerting stronger inhibition at glutamatergic terminals (Fig.
8C,D). This idea is further supported by the result that chronic
nicotine strengthened sulpiride (10 M) enhancement of sEPSC
frequency (chronic nicotine by 44  2%, n  11, p  0.0001;
Figure 4. Current–voltage relations and nicotinic currents in striatal neurons.A–D, Top, Representative records from anMSN (A1), an FS interneuron (B1), a cholinergic interneuron (C1), and an
LTS interneuron (D1), identified as described in Materials and Methods by their distinct responses to 2 s current injections (for MSN and FS: initiated from160 pA with an increment of 40 pA; for
cholinergic and LTS: initiated from80 pAwith an increment of 20 pA). Middle, Nicotinic currents recorded from voltage-clamped neurons (VH70mV) in response to a puff of ACh (100–300
M) with 0.5M atropine and 20M CNQX. The nicotinic currents in MSN (A2), FS (B2), and cholinergic neurons (C2) were blocked by 10 nMMLA. The nicotinic current in one LTS was blocked by 5
MMEC. E, In a typical MSN, nicotinic current was recorded at 5 min intervals before (Control), during (1M nicotine), and after (Wash) the perfusion of 1M nicotine, and also in the presence of
10 nM MLA. Upper bars show each condition; negative minutes denote the time before the application of nicotine. Arrows in A2–D2 and E indicate ACh puff (100 ms, 20 PSI).
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chronic vehicle by 34 3%, n 9, p 0.0001) ( p 0.01) (data
not shown).
Discussion
Upregulated42* nAChRs after chronic nicotine
are functional
Upregulation of42* nAChRnumbers is often reported in both
smokers and chronic nicotine-treated animals. It has been uncer-
tain whether the upregulated receptors are functional or desen-
sitized (Ochoa et al., 1990; Buisson and Bertrand, 2001, 2002;
Gentry and Lukas, 2002; Nashmi et al., 2003, 2007; Moroni et al.,
2006; Quik et al., 2007; Picciotto and Zoli, 2008; Lester et al.,
2009).
The present data support the idea that the upregulated
nAChRs are functional: chronic nicotine directly enhanced
MLA-resistant (presumably non-7) nicotinic currents in SNr
GABAergic neurons (Table 1). These non-7 currents were
mainly mediated by 42* nAChRs, since the currents were
blocked byDHE inWTmice and absent from4-KOmice (Fig.
1A1,A2). Also of note is that chronic nicotine increased the pro-
portion of 42* nAChRs responding to low concentrations
(10 M) of ACh (Fig. 1C2, Table 1); importantly, these recep-
tors can be activated by ambient ACh in SNr. Indeed, the 50%
increase in the firing rate of SNr GABAergic neurons chronically
exposed to nicotine, but tested in the absence of nicotine, was
measured both in slices and in vivo (Fig. 2A1,A2,C), showing that
the slice preparation preserves at least some influences on
GABAergic neurons via nAChRs.
In the dorsal striatum, all observed nicotinic currents in stri-
atal neurons were MLA sensitive (Fig. 4), implying that the re-
sponses arise from 7 nAChRs. Although puffs of 1 M nicotine
could not activate these receptors directly (data not shown),
bath-applied 1M nicotine enhanced EP-
SP–spike coupling ratio in MSNs (Fig.
5A1–A3). This effect was mimicked by
DHE (Fig. 5B1–B3) but was absent from
4-KOmice (Fig. 5C1,C2). These facts in-
dicate the existence of functional 42*
nAChRs in WT mice. Interestingly, the
desensitization or blockade of these re-
ceptors respectively by 1 M nicotine or
DHE facilitated glutamate release (Fig.
6A1,A3,B1,B3). Sulpiride prevented these
effects (Fig. 6A2,A3,B2,B3). Invoking well
established functional evidence that
42* nAChRs are localized in DA termi-
nals, we deduce that the contributing
42* nAChRs reside in DA terminals.
These contributing presynaptic nAChRs
are probably not localized in glutamater-
gic terminals in the striatum, because (1)
higher concentrations of nicotine (10
M) are needed to activate or desensitize
7 nAChRs, the principal nAChRs in glu-
tamatergic terminals of the striatum (Kai-
ser and Wonnacott, 2000; Wonnacott et
al., 2000; Marchi et al., 2002); and (2) like
previous workers, we found no evidence
for4-YFP* receptors on the corticostria-
tal glutamatergic afferents (unpublished
data).
Chronic nicotine increased the fre-
quency of sIPSCs (Fig. 3A1,A3) and en-
hanced the facilitation of glutamate
release by nicotine (Fig. 7A) andDHE (Fig. 7B). In combination
with previous findings that chronic nicotine elevates 42*
nAChRs in the striatum (Marks et al., 2004; Nashmi et al., 2007;
Perry et al., 2007), we conclude that chronic nicotine upregulates
42* nAChRs in DA terminals, and again that these receptors
are functional. This is consistent with other studies showing that
chronic nicotine increases DA levels (Fung and Lau, 1988; Court
et al., 1998), 42* nAChRs (Marks et al., 2004; Nashmi et al.,
2007; Perry et al., 2007), and42* nAChR-mediatedDA release
(McCallum et al., 2006a,b) in the striatum.
Tiers of selectivity in chronic nicotine upregulation
of nAChRs
Weobserved that chronic nicotine enhancedMLA-resistant (Fig.
1) but not MLA-sensitive nicotinic currents in SNr GABAergic
neurons, consistent with the concept that chronic exposure to
low concentrations of nicotine can upregulate 42* but not 7
nAChRs (Marks et al., 1986; Collins et al., 1994). High-affinity
nAChR binding assays previously revealed that chronic nicotine
upregulates 42* nAChRs in some but not other brain regions
(Flores et al., 1992;Marks et al., 1992; Perry et al., 1999;Nguyen et
al., 2004). A previous study demonstrated that chronic nicotine
upregulates fluorescent 4* nAChRs in midbrain GABAergic
neuron somata but not in midbrain DA neuron somata (Nashmi
et al., 2007). The present study confirms that these numerically
upregulated receptors are functional. These data indicate that
chronic nicotine upregulation of nAChRs displays selectivity in
nAChR subtype, brain region, and cell type.
SNc DA neurons project to the dorsal striatum. Although
chronic nicotine did not change the function of 42* nAChRs
in SNc DA neuron somata (Table 2), it did enhance the modula-
Figure 5. 42* nAChRsmodulateMSN neuronal excitability.A,B, InMSN, the EPSP–spike coupling ratiowas increased by 1
M nicotine (A1,A2, typical traces,A3, pooled data), and 0.3MDHE (B1,B2, typical traces,B3, pooled data). Insets ofA1,A2 are
expanded traces as indicated. CNQX (20M) blocked EPSPs. C, Nicotine (1M) did not change the EPSP–spike coupling ratio in
MSNs of4-KO mice (C1, C2, typical traces; C3, pooled data).
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tion of glutamate release by42* nAChRs in the dorsal striatum
(Fig. 7). These data extend a previous study showing that, al-
though chronic nicotine does not increase fluorescent 4*
nAChRs in the somata of SNc DA neurons, such treatment does
increase fluorescence in the dorsal striatum (Nashmi et al., 2007).
The previous study did not provide information about the local-
ization of 4* nAChRs in the several types of intrinsic neurons
and axon terminals in the dorsal striatum. We have now con-
cluded that there are no detectable nicotinic responses mediated
by4* nAChRs in the somata ofMSNs and interneurons (Fig. 4).
We have further inspected 4* nAChRs by using anti-GFP anti-
bodies to amplify the YFP signal in 4-YFP mice, which clearly
visualized 4* nAChRs in neuronal somata of the substantia
nigra (supplemental Fig. S3, available at www.jneurosci.org as
supplementalmaterial) (Nashmi et al., 2007) andDA fibers of the
dorsal striatum (Fig. 6D), but not in the somata of striatal neu-
rons (Fig. 6D). Given that in the dorsal striatum, 42* nAChRs
modulating glutamate release are located in DA terminals,
chronic nicotine upregulation of 42* nAChRs most likely oc-
curs in DA terminals. This dataset suggests that chronic nicotine
upregulation of 42* nAChRs displays an additional selectivity
in cellular compartment (soma vs axon terminal).
Chronic nicotine not only enhanced the MLA-resistant nico-
tinic currents elicited by 3–1000 M ACh but also increased the
ratio of rather low-dose (10 M) ACh-induced currents to 1
mM ACh-induced currents (Table 1). This suggests that chronic
nicotine may upregulate the higher-sensitivity (4)2(2)3 stoichi-
ometry to a greater extent than the lower-sensitivity (4)3(2)3
nAChRs, as found in several types of in vitro experiments (Buisson
and Bertrand, 2001; Lo´pez-Herna´ndez et al., 2004; Vallejo et al.,
2005; Moroni et al., 2006; Lester et al., 2009).
Chronic nicotine upregulates nAChRs through variousmech-
anisms, including increased subunit assembly via pharmacolog-
ical chaperoning (Nashmi et al., 2003; Kuryatov et al., 2005;
Lester et al., 2009), increased receptor trafficking to the plasma
membrane (Harkness and Millar, 2002; Darsow et al., 2005), re-
duced receptor turnover (Peng et al., 1994), and improved mat-
uration of the receptors (Darsow et al., 2005; Sallette et al., 2005).
Tiers of selectivity in chronic nicotine upregulation of 42*
nAChRs could result from the selectivity of pharmacological
chaperoning, interaction with accessory subunits of nAChRs, in-
teractions with auxiliary proteins such as lynx (Miwa et al., 2006),
and other unknown factors (Lester et al., 2009).
Chronic nicotine modifies synaptic circuits in nigrostriatal
DA pathways
We show that the upregulation of 42* nAChRs by chronic
nicotine influences the activity of neural circuits in the nigrostri-
atal DA pathway. In the substantia nigra (Fig. 8A,B), the en-
hanced function of42* nAChRs by chronic nicotine increased
the activity of SNr GABAergic neurons and thus strengthened
GABAergic inhibition in SNc DA neurons. This may reduce the
risk of excitotoxicity in SNc DA neurons, because GABAA recep-
tor agonists or GABA mimetic agents ameliorate some brain in-
juries by attenuating excitotoxicity (Green et al., 2000).
In the dorsal striatum the function of 42* nAChRs on the
DA terminals is also augmented by chronic nicotine, leading to
the inhibition of glutamate release (Fig. 8C,D). Increased gluta-
Figure 6. nAChRs and DA D2/D3 receptorsmodulate sEPSCs inMSNs. A, Typical traces (5 s, A1, A2) and time course (A3) of nicotine enhancement of sEPSCs in the absence (A1) or presence (A2) of
sulpiride (10M). B, DHE (0.3M) increases sEPSC frequency (B1, 5 s typical traces; B3, time course). The effect was also blocked by sulpiride (10M, B2, typical traces; B3, time course). C, MEC
enhances sEPSC frequency inWT but not in4-KOmice (C1, representative traces; C2, time course).D, Immunohistochemistry of TH (red),4-YFP* nAChRs (green), and their colocalization (arrow)
in the dorsal striatum. Data in time course and summary are shown as mean SEM.
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mate release occurs in the striatumboth of
PD patients and of PD animal models
(Calabresi et al., 2000; Koutsilieri andRie-
derer, 2007; Boulet et al., 2008) andmight
contribute to dyskinesia following long-
term L-DOPA treatment. Memantine and
amantadine, two NMDA receptor antago-
nists, relieve dyskinesia (Parsons et al.,
1999; Steece-Collier et al., 2000; Hadj
Tahar et al., 2004). Coincidently, chronic
nicotine effectively controls the dyskine-
sia when coapplied with L-DOPA (Quik et
al., 2008). We now report that nicotine
increases the proportion of corticostriatal
presynaptic action potentials leading to
MSN action potentials (Fig. 5), provid-
ing a possible synaptic basis for this ap-
parent therapeutic effect. The proposed
mechanism (Fig. 8) is indirect, and
other possible, albeit more complicated,
explanations might also be consistent
with the data.
The subcellular selectivity of 4*
nAChR upregulation by chronic nicotine
exposure may alter the overall function of
basal ganglia circuitry. The two major
cholinergic cell types that influence DA
release are themesopontine neurons, which
project to substantia nigra, and the giant
intrinsic cholinergic interneurons of stri-
atum. Because chronic nicotine does not
upregulate 4* nAChRs on DA neuron
somata and dendrites in SNc, but does so
onDAneuron axon terminals in striatum,
one expects chronic nicotine to cause a
relatively stronger influence by the latter
cholinergic cell types. Despite the lower
DA neuron firing rate caused by events in
substantia nigra, the direct presynaptic
excitation may maintain striatal DA re-
lease at near-normal levels. Because the
DA terminals are rather distant from the
soma, one does not expect the nicotinic
depolarization to become excitotoxic by
extensively perturbing somatodendritic
metabolism, and it would not counteract
the excitotoxic-sparing mechanism.
Chronic exposure to nicotine itself may
have advantages overGABAmimetic agents
and glutamate antagonists as neuroprotec-
tive agents inPD: (1) nicotine effects are rel-
atively mild in general, (2) chronic nicotine
leads to long-termmodification of synaptic
circuits by upregulating 42* nAChRs,
and (3) chronic nicotine upregulation of
42* nAChRs presents tiers of selectivity:
brain regions, neuronal cell types, cellular
compartments, and stoichiometry, fortu-
itously restricting the targets and reducing
the side effects. However, nicotine analogs
that are highly selective for 42* nAChRs
might be better therapeutic choices, espe-
cially if they efficiently upregulate these re-
Figure 7. Chronic nicotine augments nicotinic modulation of spontaneous EPSCs in MSNs. A, chronic nicotine augments nico-
tine (1M) enhancement of spontaneous EPSC frequency (A1, 5 s typical traces; A2, summarized time course).B, Chronic nicotine
strengthens DHE (0.3M) enhancement of spontaneous EPSC frequency (B1, 5 s typical traces; B2, summarized time course).
C, Chronic nicotine reduces baseline sEPSC frequency (C1, 5 s typical traces; C2, pooled data for sEPSC frequency). Data in summa-
rized time courses are shown as mean SEM.
Figure 8. Diagramof chronic nicotinemodulationof nigrostriatal pathway.A, In untreated substantia nigra, AChactivates nAChRs on
bothSNrGABAergicneuronsandSNcDAneurons.B,Afterchronicnicotinetreatment, thenAChRs intheSNrGABAergicneuronsomata,but
not those in the SNc DA neuron somata, are upregulated. The activation of nAChRs by endogenous ACh causes hyperactivity of SNr
GABAergic neurons, which inhibits SNc DA neurons. C, In untreated striatum, ACh activates nAChRs on DA terminals and facilitates DA
release. DA activates D2/D3 receptors (D2R) on glutamatergic terminals and inhibits glutamate (Glu) release.D, Chronic nicotine upregu-
lates nAChRs onDA terminals, enhances DA release, and causes a further inhibition of Glu release.
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ceptors in SNr GABAergic neurons and in dorsal striatum DA
terminals.
In conclusion, 42* nAChRs can be upregulated by chronic
nicotine and remain functional. The upregulation shows selectiv-
ity in nAChR subtype, neuronal cell type, cellular compartment,
and possibly stoichiometry. These tiers of selectivity may reshape
the activity of neural circuits in the nigrostriatal DA pathway,
protecting DA neurons from excitotoxic damage by moderating
burst firing initiated at the soma, while also preserving normal
levels of DA release at the striatal DA terminals.
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